Regeneron Pharmaceuticals (REGN) Balance Sheet: Assets & Liabilities

Regeneron Pharmaceuticals (REGN) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Regeneron Pharmaceuticals reported total assets of $40.56B and total liabilities of $9.30B. Shareholders' equity was $31.26B, up 6.5% from $29.35B a year earlier. Total debt stood at $2.71B against $8.61B in cash and short-term investments, a net cash position of $5.90B. That puts debt-to-equity at 0.09, compared with 0.07 a year earlier.

Regeneron Pharmaceuticals Balance Sheet Analysis

Values in billions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Regeneron Pharmaceuticals, Inc. (REGN) - Annual data in billions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	3.12	2.49	2.73	3.11	2.89	2.19	1.62	1.47	0.81
Short-Term Investments	5.49	6.52	8.11	4.64	2.81	1.39	1.60	1.34	0.60
Cash & Short-Term Investments	8.61	9.01	10.84	7.74	5.69	3.59	3.21	2.81	1.41
Accounts Receivable	5.74	6.21	5.67	5.33	6.04	4.11	2.79	2.24	1.97
Inventory	3.20	3.09	2.58	2.40	1.95	1.92	1.42	1.15	0.73
Other Current Assets	0.47	0.35	0.39	0.41	0.33	0.16	0.27	0.24	0.23
Total Current Assets	18.02	18.66	19.48	15.88	14.01	9.78	7.69	7.96	5.60
Non-Current Assets
Property, Plant & Equipment (Net)	5.12	4.60	4.15	3.76	3.48	3.22	2.89	2.58	2.36
Long-Term Investments	10.26	8.90	5.40	6.59	6.84	3.14	3.26	1.76	1.49
Intangible Assets	1.26	1.15	1.04	0.92	0.01	0.00	0.00	0.00	0.00
Other Non-Current Assets	1.82	4.45	0.44	2.06	0.22	0.17	0.14	0.13	0.08
Total Non-Current Assets	22.54	19.10	13.60	13.33	11.42	7.38	7.12	5.29	4.43
Total Assets	40.56	37.76	33.08	29.21	25.43	17.16	14.81	11.73	8.76
Current Liabilities
Accounts Payable	0.94	0.79	0.61	0.59	0.56	0.48	0.42	0.22	0.18
Short-Term Debt	0.00	0.00	0.00	0.00	0.72	0.00	0.00	0.00	0.00
Accrued Liabilities	2.88	2.53	2.35	2.07	2.21	-	-	-	-
Deferred Revenue	0.55	0.63	0.46	0.48	0.44	0.58	0.59	0.45	0.32
Other Current Liabilities	2.88	2.31	2.36	2.07	1.88	1.62	1.20	0.75	0.64
Total Current Liabilities	4.37	3.94	3.42	3.14	3.93	2.70	2.10	1.44	1.14
Non-Current Liabilities
Long-Term Debt	2.71	1.98	1.98	1.98	1.98	2.70	0.71	0.71	0.70
Other Non-Current Liabilities	2.02	1.76	0.85	0.71	0.68	0.69	0.80	0.55	0.95
Total Non-Current Liabilities	4.93	4.46	3.68	3.41	2.73	3.44	1.62	1.53	1.48
Total Liabilities	9.30	8.41	7.11	6.55	6.67	6.14	3.72	2.98	2.62
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	35.80	31.67	27.26	23.31	18.97	10.89	7.38	5.25	2.95
Accumulated Other Comprehensive Income	0.08	-0.01	-0.08	-0.24	-0.03	0.03	0.02	-0.01	0.00
Treasury Stock	18.61	15.17	12.56	10.35	-	-	-	-	-
Additional Paid-in Capital	-4.62	-2.31	11.35	9.95	-0.17	0.10	3.69	3.52	3.20
Shares Outstanding	0.11	0.11	0.11	0.11	-	-	-	-	-
Total Stockholders' Equity	31.26	29.35	25.97	22.66	18.77	11.03	11.09	8.76	6.14
Total Liabilities & Equity	40.56	37.76	33.08	29.21	25.43	17.16	14.81	11.73	8.76

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Regeneron Pharmaceuticals Balance Sheet

How much debt does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals had total debt of $2.71B as of Dec 31, 2025, against $8.61B in cash and short-term investments. Its debt-to-equity ratio was 0.09. Total debt was $1.98B a year earlier.

What are Regeneron Pharmaceuticals's total assets?

Regeneron Pharmaceuticals reported total assets of $40.56B as of Dec 31, 2025, up 7.4% from $37.76B a year earlier. Total liabilities were $9.30B.

What is Regeneron Pharmaceuticals's shareholders' equity?

Regeneron Pharmaceuticals's shareholders' equity was $31.26B as of Dec 31, 2025, or about $295.67 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition